Introduction

Anhedonia is the reduced ability to feel pleasure or interest in things you would normally enjoy: the food that used to taste good, the friends you used to look forward to seeing, the hobby that once absorbed you. It is a core symptom of depression, and it is one of the experiences I hear described most often in my consulting room, usually in a self-critical way. People tell me they feel flat, switched off, or numb, and then they blame themselves for it.

So let me say this clearly at the outset. Anhedonia is not laziness, and it is not ingratitude. It is not a sign that you are broken or that you have failed to appreciate your life. It has real biological drivers, and understanding this can be a relief in itself. In this article I want to walk through what we know: the brain's reward system and the role of dopamine, the impact of chronic stress and trauma, the link with depression, and the ways in which some medications, including certain antidepressants, can play a part. I will also cover what tends to help.

One important caveat before we start. When we talk about anhedonia, we are honestly still learning. We cannot say with certainty what causes it in any one person. What we can describe reasonably well is how reward works in the brain, and the common causes of anhedonia which is what I will focus on here.

The Brain's Reward System

To understand anhedonia, it helps to explain how the brain registers reward in the first place.

Deep in the brain sits what is often called the reward circuit, and dopamine is the key messenger within it. This is a complex system, but in simple terms, a network known as the mesolimbic dopamine pathway carries signals about how rewarding something is.

Two structures, the ventral striatum and the nucleus accumbens, act as a kind of signalling hub, while the prefrontal cortex, the thinking part at the front of the brain, weighs things up and decides how much they matter [Ref 1] [Ref 2]. When this system is working as usual, a good meal, a warm conversation or a small achievement all register as pleasurable and worth pursuing.

What studies have found is that in anhedonia and depression, the activity and functioning of this network loses its balance [Ref 3] [Ref 1].

The Cleveland Clinic described one of these changes in a way I find useful for patients: there is reduced activity in the ventral striatum, sometimes called the brain's pleasure centre, which is the area that handles dopamine [Ref 2].

When that activity dips, rewards that should feel meaningful instead register as flat. Nothing has "gone wrong" with you as a person. It is more that the volume on the reward signal has been turned down.

The distinction: wanting, liking, and learning

Here is a distinction that often makes sense of people's experience. Researchers separate reward into "wanting", "liking", and "learning". Each can be thought of as a component to the reward system, and each can be impacted in anhedonia.

The "wanting", refers to the drive, the motivation, and the anticipation of something rewarding. The "liking", relates to the in-the-moment enjoyment. Finally, the "learning" reflects the internal feedback, memory, and reinforcement of how rewarding an event was [Ref 3].

These 3 aspects of reward may be impacted by different shifts in brain activity. This may explain why, for many people, motivation is the first thing to disappear [Ref 4] [Ref 3]. You might still, in theory, enjoy something once you are doing it, but you cannot summon the drive to start.

Patients often describe this as knowing they used to love something while feeling completely unable to reach for it. This gap between wanting and liking is a common part of anhedonia.

Chronic Stress

Stress that goes on and on, rather than a single difficult week, appears to leave its mark on this same reward circuit. Sustained stress may dampen dopamine signalling and, over time, reshape how the reward pathway behaves.

Much of the detailed evidence here comes from animal research, so I want to be careful with my language: animal studies suggest that chronic stress alters the firing of dopamine neurons in the reward pathway [Ref 1]. We should not overstate this as proven in humans, but it fits with what we see clinically, where long periods of pressure so often precede a loss of enjoyment.

Trauma

Trauma is another important thread. Experiencing trauma, whether or not someone goes on to receive a diagnosis of post-traumatic stress disorder, is linked with reduced reward responsiveness and altered connectivity within the reward circuit [Ref 5].

In other words, difficult experiences may change how readily the brain registers pleasure. If you have been through something hard and have noticed that the world feels muted since, this is a recognised pattern, not a personal shortcoming.

Depression

Much of this connects back to depression. Anhedonia is a core symptom of depression, one of the central experiences clinicians look for, and it affects a large proportion of people who become depressed. The reward-circuit changes I described earlier are part of the same picture [Ref 4].

So if you are depressed and have lost your ability to take pleasure in things, you are not experiencing something separate or unusual. You are experiencing one of depression's defining features, and it is one that tends to lift as the depression itself is treated.

Medication, Including Some Antidepressants

This is an area I am asked about a great deal, and it deserves a careful, balanced explanation.

Some antidepressants, particularly SSRIs and SNRIs, can cause what we call emotional blunting. Studies suggest this affects somewhere between 40 and 60% of people taking these medications [Ref 6] [Ref 7].

Emotional blunting reduces sensitivity to reward, and understandably it can feel very much like anhedonia: a sense of dullness, flattening or caring less about things.

I want to put this into context, because it matters. Depression itself blunts pleasure, often severely, and for many people recovery improves it.

Antidepressants help many people, and for some they are genuinely life-changing or life-saving. The point of raising medication-induced blunting is not to frighten anyone away from treatment. It is simply to say that if you have started a medication and noticed your enjoyment fade, that experience is real, recognised, and worth talking about rather than enduring alone.

Other Contributors

Anhedonia is not exclusive to depression. It can appear in, or be worsened by, a number of other conditions, including Parkinson's disease, schizophrenia and substance use, and even poor sleep can take a toll on our capacity for pleasure [Ref 2]. If your low enjoyment sits alongside other symptoms, it is always worth an honest conversation with a professional who can look at the whole picture.

What Helps

The most important principle is this: to help anhedonia, we usually treat the underlying cause, and often that means treating the depression it sits within. As depression lifts, the reward system tends to come back online and pleasure gradually returns.

There is also a growing and encouraging field of neuromodulation research looking directly at the reward circuit. Independent studies of DLPFC tDCS and rTMS, two techniques that gently stimulate an area at the front of the brain, have reported promising effects on anhedonia [Ref 10].

For example, a randomised, sham-controlled trial of left-DLPFC tDCS found a significant improvement in anhedonia scores [Ref 11], and separate rTMS research has reported reductions in anhedonia with large effect sizes [Ref 12].

There is also a growing and encouraging field of neuromodulation research looking directly at the reward circuit. Independent studies of DLPFC tDCS and rTMS, two techniques that gently stimulate an area at the front of the brain, have reported promising effects on anhedonia [Ref 10].

For example, a randomised, sham-controlled trial of left-DLPFC tDCS found a significant improvement in anhedonia scores [Ref 11], and separate rTMS research has reported reductions in anhedonia with large effect sizes [Ref 12].

These are independent findings, not claims about any single product, but they point to an area where newer treatments are actively being developed, and that gives me real optimism.

This is also the area my own work sits within. Flow is a non-invasive, FDA approved and CE certified home treatment for depression that delivers a gentle electrical current to the dorsolateral prefrontal cortex, or DLPFC, the area involved in mood regulation [Ref 13].

It is available on the NHS in 4 trusts, with ongoing NHS pilots, and can be used for all levels of depression, from mild to severe. In real-world data, 77% of users report improvement within three weeks [Ref 14].

Flow is a treatment for depression, and I would not describe it as a treatment for anhedonia specifically, but because anhedonia so often travels with depression, it forms part of the wider set of options worth knowing about.

One of our users, Mike, a musician living with depression and ADHD, described the moment his interest in things came back in a way that has always stayed with me [Ref 15]:

Key Takeaways

If you take nothing else from this, take this: anhedonia has real biological drivers, and it is not a character flaw. The threads we have covered are the reward circuit and dopamine, chronic stress, trauma, depression itself, and, for some people, certain medications. The reassuring part is that most underlying causes are treatable. Whether through treating depression, behavioural activation, or the newer neuromodulation options now emerging, there are genuine reasons for hope.

Closing

In my years of practice, I have found that understanding why pleasure has faded is often the first step towards getting it back. It lifts the self-blame, and it points towards what can actually help. If any of this sounds like you, please do not sit with it alone. Talk to your doctor or a qualified healthcare professional who can look at your individual situation and help you decide on the right next step.

References

^{[1] Anhedonia and the brain reward circuitry in depression (NIH/PMC): the mesolimbic dopamine pathway, ventral striatum, nucleus accumbens and prefrontal cortex, plus animal evidence that chronic stress alters dopamine neuron firing. https://pmc.ncbi.nlm.nih.gov/articles/PMC4626008/}

^{[2] Cleveland Clinic, Anhedonia: reduced ventral striatum activity, and other contributors including Parkinson's disease, schizophrenia, substance use and poor sleep. https://my.clevelandclinic.org/health/symptoms/25155-anhedonia}

^{[3] Characterizing anhedonia: a systematic review of neuroimaging studies (NIH/PMC): loss of balance in the reward network, and the wanting, liking and learning components of reward. https://pmc.ncbi.nlm.nih.gov/articles/PMC7395022/}

^{[4] Anhedonia and Depressive Disorders (review, NIH/PMC): anhedonia as a core symptom of depression, motivation often affected first, and the associated reward-circuit changes. https://pmc.ncbi.nlm.nih.gov/articles/PMC10335915/}

^{[5] Anhedonia in trauma-exposed individuals (NIH/PMC): reduced reward responsiveness and altered reward-circuit connectivity after trauma, with or without a PTSD diagnosis. https://pmc.ncbi.nlm.nih.gov/articles/PMC6233731/}

^{[6] Emotional blunting in major depressive disorder (review, NIH/PMC): prevalence of emotional blunting on SSRIs and SNRIs, and reduced reward sensitivity. https://pmc.ncbi.nlm.nih.gov/articles/PMC8712545/}

^{[7] University of Cambridge (2023), Scientists explain emotional blunting caused by common antidepressants: supporting evidence for the 40 to 60% figure and the reward-sensitivity mechanism. https://www.cam.ac.uk/research/news/scientists-explain-emotional-blunting-caused-by-common-antidepressants}

^{[9] Richards et al. (2016), COBRA trial, The Lancet: behavioural activation as effective as CBT and cheaper to deliver. https://pmc.ncbi.nlm.nih.gov/articles/PMC5007415/}

^{[10] Serretti (2025), Anhedonia: current and future treatments (review): behavioural activation re-training the reward response, and promising DLPFC tDCS and rTMS findings for anhedonia. https://pmc.ncbi.nlm.nih.gov/articles/PMC11930767/}

^{[11] Transcranial direct current stimulation for anhedonia (Journal of Affective Disorders, 2024): a randomised, sham-controlled trial of left-DLPFC tDCS showing significant improvement in anhedonia scores. https://pubmed.ncbi.nlm.nih.gov/38232776/}

^{[12] DLPFC rTMS and anhedonia (Scientific Reports, 2025): reductions in anhedonia with large effect sizes. https://www.nature.com/articles/s41598-024-85057-w}

^{[13] Flow Neuroscience, How It Works: tDCS delivers a gentle electrical current to the dorsolateral prefrontal cortex (DLPFC), the area involved in mood regulation. https://www.flowneuroscience.com/how-it-works/}

^{[14] Flow Neuroscience, Evidence: 77% of users report improvement within three weeks (real-world data). https://www.flowneuroscience.com/evidence/}

^{[15] Written testimonial from a Flow user, on file. Quoted verbatim with permission.}